- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05660811
Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients (SAFE LAAC CKD)
Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events Following Left Atrial Appendage Closure - Chronic Kidney Disease (SAFE LAAC CKD). Comparative Health Effectiveness Ancillary Study - PILOT
Study Overview
Status
Conditions
Detailed Description
Background:
Transcatheter left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation in preventing cardioembolic strokes associated with atrial fibrillation. However, an optimal antithrombotic treatment regimen following successful LAAC remains an unresolved issue and may significantly contribute to long-term safety and efficacy. Nowadays LAAC is mainly performed in patients with contraindications for oral anticoagulation due to high bleeding risk. Dialyzed patients with end-stage renal disease and atrial fibrillation have simultaneously high thromboembolic and bleeding risk. Such patients were excluded from randomized trials and data on the LAAC efficacy in this population is limited thus prospective studies are warranted.
Objective:
SAFE-LAAC CKD Trial has been designed as a comparative health effectiveness study with the following aims:
- compare the safety and efficacy of 30 days vs. 6 months of dual antiplatelet therapy following LAAC with Amplatzer or WATCHMAN device (randomized comparison)
- compare the safety and efficacy of stopping all antithrombotic and antiplatelet agents 6 months after LAAC vs. long-term treatment with a single antiplatelet agent (nonrandomized comparison)
Patient population:
Patients (n=80) with the end-stage renal disease treated with chronic haemodialysis or peritoneal dialysis, after successful LAAC with Amplatzer or WATCHMAN device
Perspective:
Results of this pilot trial will provide: 1. data to aid practitioners and guideline writers recommend the most optimal antithrombotic treatment after LAAC, 2. data on the safety and efficacy of LAAC in dialyzed patients, and 3. data to support power calculations for designing future randomized trials.
Methodology:
SAFE LAAC CKD has been designed as a multicenter (planned contribution of 7 centers in Poland), open-label, comparative health effectiveness trial with central, independent adjudication of events comprising the primary end-point. The first part of the trial is randomized and after 6 months of follow-up continues for another 12 months as a non-randomized study.
Timeline:
The duration of the trial has been planned for 5 years. The enrollment phase has been planned for 3 years.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Radoslaw Pracon, MD PhD
- Phone Number: +48 22 343 43 42
- Email: rpracon@ikard.pl
Study Contact Backup
- Name: Marcin Demkow, MD PhD
- Phone Number: +48 22 343 43 42
- Email: mdemkow@ikard.pl
Study Locations
-
-
Mazowieckie
-
Warsaw, Mazowieckie, Poland, 04-628
- Recruiting
- National Institute of Cardiology
-
Contact:
- Radoslaw Pracon, MD PhD
- Phone Number: +48 22 343 43 42
- Email: rpracon@ikard.pl
-
Contact:
- Marcin Demkow, MD PhD
- Phone Number: +48 22 343 43 42
- Email: mdemkow@ikard.pl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Successful left atrial appendage occlusion with Amplatzer or WATCHMAN device within 37 days prior to randomization
- End-stage renal disease treated with chronic haemodialysis or peritoneal dialysis
- Participant's age 18 years or older at the time of signing the informed consent form
- Participant is willing to follow all study procedures; especially the randomized antiplatelet treatment regimen
- Participant is willing to sign the study informed consent form
Exclusion Criteria:
- Indications to dual antiplatelet therapy other than left atrial appendage occlusion at the time of enrollment and/or predicted appearance of such indications within the duration of the trial (e.g. planned coronary revascularization)
- Indications to anticoagulation at the time of enrollment and/or predicted appearance of such indications within the duration of the trial (e.g. pulmonary embolism). Does not apply to anticoagulation used during dialysis
- Known allergy to clopidogrel and/or acetylsalicylic acid precluding its administration as specified by the protocol
- Peridevice leak >5mm on imaging study preceding enrollment
- Left atrial thrombus on an imaging study performed after successful left atrial appendage closure but before enrollment
- Life expectancy of fewer than 18 months
- Participation in other clinical studies with experimental therapies at the time of enrollment and/or preceding 3 months
- Women who are pregnant or breastfeeding; women of childbearing potential who do not consent to apply at least two methods of contraception. This criterion does not apply to women 2 years post menopause (with a negative pregnancy test 24 hours before randomization if <55 years old) or after surgical sterilization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 30 days DAPT and long-term treatment with a single antiplatelet agent
short postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
|
continuing long-term treatment with single antiplatelet agent
continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
|
Other: 6 months DAPT and long-term treatment with a single antiplatelet agent
extended postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
|
continuing long-term treatment with single antiplatelet agent
stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
|
Other: 30 days DAPT and 6 months treatment with a single antiplatelet agent
short postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
|
continuing single antiplatelet agent up until 6 months
continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
|
Other: 6 months DAPT and 6 months treatment with a single antiplatelet agent
extended postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
|
continuing single antiplatelet agent up until 6 months
stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy (a composite of ischemic stroke, transient ischaemic attack, peripheral embolism, nonfatal myocardial infarction, cardiovascular mortality, all-cause mortality, left atrial appendage thrombus)
Time Frame: 17 months
|
Event rates reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Safety (moderate and/or severe bleeding (BARC type 2, 3, and 5)
Time Frame: 17 months
|
Event rates reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ischemic stroke
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Transient ischaemic attack
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Peripheral embolism
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Nonfatal myocardial infarction
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Cardiovascular mortality
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
All-cause mortality
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Moderate and/or severe bleeding (BARC type 2,3, and 5)
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Left atrial appendage thrombus
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Any bleeding
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
New moderate or major (≥4 mm) ischemic brain lesions on magnetic resonance imaging
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Change in cognition score as detected by the Addenbrooke's cognitive examination (ACE-III)
Time Frame: 17 months
|
ACE-III is a screening test that is composed of tests of attention, orientation, memory, language, visual perceptual, and visuospatial skills.
The total range of raw score is 0-100.
A higher score indicates more intact cognitive functioning.
|
17 months
|
Dialysis access thrombosis
Time Frame: 17 months
|
Event rate reported per 100 patient-years (calculated as 100*Number of Participants with events/Total patient-years);
|
17 months
|
Safety and efficacy of the procedure in the periprocedural period and 1-month follow-up based on registry data
Time Frame: 1-month
|
1-month event rate of: cardiac arrest, device embolism, tamponade, pericardial effusion, stroke/TIA/myocardial infarction/peripheral embolus, access site bleeding/vascular complications, bleeding complications unrelated to access site (Number of Participants with event/Total patient number)
|
1-month
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of new ischemic brain lesions on magnetic resonance imaging
Time Frame: 17 months
|
17 months
|
Volume of new ischemic brain lesions on magnetic resonance imaging
Time Frame: 17 months
|
17 months
|
The change from baseline in the cumulative dose of heparin anticoagulation used during haemodialysis
Time Frame: 17 months
|
17 months
|
The change from baseline in the dose of erythropoietin used
Time Frame: 17 months
|
17 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Radoslaw Pracon, MD PhD, Coronary and Structural Heart Diseases Department, National Institute of Cardiology, Warsaw, Poland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CKD/1458/21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on long-term treatment with a single antiplatelet agent
-
National Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
Butler HospitalAmerican Foundation for Suicide PreventionCompletedSchizophrenia | SuicideUnited States
-
Penn State UniversityNational Institute of Mental Health (NIMH)Completed
-
Fundación Pública Andaluza para la gestión de la...Spanish Clinical Research Network - SCReN; CIBER (Infectious diseases)Recruiting
-
AstraZenecaCompletedHealthy Subjects | BioavailabilityGermany
-
Prof. Dr. Jörg LeuppiCompletedCovid19 | Vitamin D Deficiency | Corona Virus Infection | ARDS | SARS-CoV Infection | CoronavirusSwitzerland
-
AstraZenecaCompletedPharmacokinetics | Bioequivalence | Healthy Japanese SubjectsUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisFonds de Dotation ACTIONNot yet recruiting
-
Shanghai University of Traditional Chinese MedicineFudan University; Shanghai Chest HospitalCompleted
-
Diagram B.V.Completed